Optimizing Management Beyond Triple Therapy in Stable Severe Chronic Obstructive Pulmonary Disease: Efficacy of Adjunctive Oral Doxophylline in a Randomized Controlled Trial
Journal of the Association of Physicians of India · 2025
DOI: 10.59556/japi.73.1207 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Association of Physicians of India, 2025. Verfasst von Bhagiradhi Thimmapuram und 3 weiteren Autor:innen. Beteiligte Einrichtung: Junior Resident, Department of Respiratory Medicine, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India, Orcid: https://orc…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Theophylline.
Themen: COPD
Abstract (Originalsprache)
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition commonly managed with triple inhaler therapy comprising long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA), and inhaled corticosteroid (ICS). Despite optimal inhalation therapy, many patients continue to experience persistent symptoms. Doxophylline, a novel xanthine derivative, offers bronchodilator and anti-inflammatory benefits with a more favorable safety profile than traditional methylxanthines.
Objective
To assess the efficacy, safety, and tolerability of oral doxophylline in addition to triple inhaler therapy in patients with stable severe COPD. Materials and methods: In this randomized controlled trial, 78 patients were allocated to group A (triple therapy + doxophylline 650 mg once daily) and group B (triple therapy alone). Assessment included the COPD assessment test (CAT score), C-reactive protein (CRP), spirometry parameters (FEV₁, FEV₁%, FEV₁/FVC), adverse events, and evaluations were performed on days 0 and 90.
Results
By day 90, group A showed greater improvement in CAT score (7.94 ± 4.17 vs 10.06 ± 3.99; p = 0.033) and CRP (12.2 ± 4.47 vs 15.33 ± 5.37 mg/L; p = 0.01). Spirometry gains were comparable: FEV₁ (0.97 ± 0.23 vs 0.96 ± 0.26 L/minute; p = 0.872), FEV₁% predicted (49.10 ± 8.73 vs 48.69 ± 9.72%; p = 0.482), and FEV₁/FVC% (54.09 ± 6.57 vs 52.89 ± 6.95%; p = 0.397). Mild adverse events including palpitations (14.29%), tremors (8.57%), and nausea (2.86%) were more frequent in group A but were generally tolerated.
Conclusion
Adjunctive oral doxophylline significantly improved symptom burden and systemic inflammation in patients with stable severe COPD without conferring additional spirometric benefits. Although mild adverse effects were observed, doxophylline was overall well tolerated and may represent a viable adjunctive option in selected COPD patients with persistent symptoms despite optimized inhaler therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Junior Resident, Department of Respiratory Medicine, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India, Orcid: https://orcid.org/0009-0008-2136-7879.
- Professor, Department of Respiratory Medicine, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India, Orcid: https://orcid.org/0000-0002-3943-4880, Corresponding Author.
- Assistant Professor, Department of Respiratory Medicine, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India.
- Head of the Department, Department of Respiratory Medicine, SRM Medical College Hospital and Research Centre, Chennai, Tamil Nadu, India, Orcid: https://orcid.org/0000-0002-4672-0578.
Zitieren
APA
Thimmapuram, B., Suriyan, S., Sakthivel, N., & Nagesh, N. J. (2025). Optimizing Management Beyond Triple Therapy in Stable Severe Chronic Obstructive Pulmonary Disease: Efficacy of Adjunctive Oral Doxophylline in a Randomized Controlled Trial. Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.73.1207
Vancouver
Thimmapuram B, Suriyan S, Sakthivel N, Nagesh NJ. Optimizing Management Beyond Triple Therapy in Stable Severe Chronic Obstructive Pulmonary Disease: Efficacy of Adjunctive Oral Doxophylline in a Randomized Controlled Trial. Journal of the Association of Physicians of India. 2025. doi:10.59556/japi.73.1207
BibTeX
@article{Thimmapuram2025,
author = {Thimmapuram, Bhagiradhi and Suriyan, Subramanian and Sakthivel, Nagarjun and Nagesh, Nalini Jayanthi},
title = {Optimizing Management Beyond Triple Therapy in Stable Severe Chronic Obstructive Pulmonary Disease: Efficacy of Adjunctive Oral Doxophylline in a Randomized Controlled Trial},
journal = {Journal of the Association of Physicians of India},
year = {2025},
doi = {10.59556/japi.73.1207}
}
EUVIMED